FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2114068656> ?p ?o ?g. }

• W2114068656 endingPage "254" @default.
• W2114068656 startingPage "243" @default.
• W2114068656 abstract "During wound healing, fibroblasts are recruited from the surrounding tissue to accomplish repair. The requisite migration and proliferation of the fibroblasts is promoted by growth factors including those that activate the epidermal growth factor receptor (EGFR). Counterstimulatory factors in wound fluid are postulated to limit this response; among these factors is the ELR-negative CXC chemokine, interferon inducible protein-10 (IP-10). We report here that IP-10 inhibited EGF- and heparin-binding EGF-like growth factor-induced Hs68 human dermal fibroblast motility in a dose-dependent manner (to 52% and 44%, respectively, at 50 ng/ml IP-10), whereas IP-10 had no effect on either basal or EGFR-mediated mitogenesis (96 +/- 15% at 50 ng/ml). These data demonstrate for the first time a counterstimulatory effect of IP-10 on a specific induced fibroblast response, EGFR-mediated motility. To define the molecular basis of this negative transmodulation of EGFR signaling, we found that IP-10 did not adversely impact receptor or immediate postreceptor signaling as determined by tyrosyl phosphorylation of EGFR and two major downstream effectors phospholipase C-gamma and erk mitogen-activated protein kinases. Morphological studies suggested which biophysical steps may be affected by demonstrating that IP-10 treatment resulted in an elongated cell morphology reminiscent of failure to detach the uropod; in support of this, IP-10 pretreatment inhibited EGF-induced cell detachment. These data suggested that calpain activity may be involved. The cell permeant agent, calpain inhibitor I, limited EGF-induced motility and de-adhesion similarly to IP-10. IP-10 also prevented EGF- induced calpain activation (reduced by 71 +/- 7%). That this inhibition of EGF-induced calpain activity was secondary to IP-10 initiating a cAMP-protein kinase A-calpain cascade is supported by the following evidence: (a) the cell permeant analogue 8-(4-chlorophenylthio)-cAMP (CPT-cAMP) prevented EGF-induced calpain activity and motility; (b) other ELR-negative CXC chemokines, monokine induced by IFN-gamma and platelet factor 4 that also generate cAMP, inhibited EGF-induced cell migration and calpain activation; and (c) the protein kinase A inhibitor Rp-8-Br-cAMPS abrogated IP-10 inhibition of cell migration, cell detachment, and calpain activation. Our findings provide a model by which IP-10 suppresses EGF-induced cell motility by inhibiting EGF-induced detachment of the trailing edges of motile cells." @default.
• W2114068656 created "2016-06-24" @default.
• W2114068656 creator A5038986832 @default.
• W2114068656 creator A5053223845 @default.
• W2114068656 creator A5076666408 @default.
• W2114068656 creator A5087720227 @default.
• W2114068656 date "1999-07-12" @default.
• W2114068656 modified "2023-10-16" @default.
• W2114068656 title "Ip-10 Inhibits Epidermal Growth Factor–Induced Motility by Decreasing Epidermal Growth Factor Receptor–Mediated Calpain Activity" @default.
• W2114068656 cites W11047703 @default.
• W2114068656 cites W1508288050 @default.
• W2114068656 cites W1925247341 @default.
• W2114068656 cites W1963588589 @default.
• W2114068656 cites W1971934781 @default.
• W2114068656 cites W1972200772 @default.
• W2114068656 cites W1972774722 @default.
• W2114068656 cites W1988688738 @default.
• W2114068656 cites W1989643615 @default.
• W2114068656 cites W1993312924 @default.
• W2114068656 cites W1997169885 @default.
• W2114068656 cites W1998605540 @default.
• W2114068656 cites W2000398400 @default.
• W2114068656 cites W2002217163 @default.
• W2114068656 cites W2002593980 @default.
• W2114068656 cites W2010052831 @default.
• W2114068656 cites W2010087085 @default.
• W2114068656 cites W2022541364 @default.
• W2114068656 cites W2032338993 @default.
• W2114068656 cites W2041827175 @default.
• W2114068656 cites W2042502127 @default.
• W2114068656 cites W2048475311 @default.
• W2114068656 cites W2052378979 @default.
• W2114068656 cites W2053406714 @default.
• W2114068656 cites W2065447462 @default.
• W2114068656 cites W2067635861 @default.
• W2114068656 cites W2093274726 @default.
• W2114068656 cites W2097672376 @default.
• W2114068656 cites W2099253537 @default.
• W2114068656 cites W2105848821 @default.
• W2114068656 cites W2117910395 @default.
• W2114068656 cites W2118375252 @default.
• W2114068656 cites W2150069346 @default.
• W2114068656 cites W2151370338 @default.
• W2114068656 cites W2153869022 @default.
• W2114068656 cites W2155958456 @default.
• W2114068656 cites W2161155632 @default.
• W2114068656 cites W2162164344 @default.
• W2114068656 cites W2183079276 @default.
• W2114068656 cites W2410910046 @default.
• W2114068656 cites W2429660217 @default.
• W2114068656 cites W4244794328 @default.
• W2114068656 cites W4376097497 @default.
• W2114068656 cites W1987504336 @default.
• W2114068656 doi "https://doi.org/10.1083/jcb.146.1.243" @default.
• W2114068656 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2199733" @default.
• W2114068656 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10402474" @default.
• W2114068656 hasPublicationYear "1999" @default.
• W2114068656 type Work @default.
• W2114068656 sameAs 2114068656 @default.
• W2114068656 citedByCount "65" @default.
• W2114068656 countsByYear W21140686562012 @default.
• W2114068656 countsByYear W21140686562013 @default.
• W2114068656 countsByYear W21140686562014 @default.
• W2114068656 countsByYear W21140686562015 @default.
• W2114068656 countsByYear W21140686562016 @default.
• W2114068656 countsByYear W21140686562017 @default.
• W2114068656 countsByYear W21140686562018 @default.
• W2114068656 countsByYear W21140686562019 @default.
• W2114068656 countsByYear W21140686562020 @default.
• W2114068656 countsByYear W21140686562021 @default.
• W2114068656 countsByYear W21140686562022 @default.
• W2114068656 crossrefType "journal-article" @default.
• W2114068656 hasAuthorship W2114068656A5038986832 @default.
• W2114068656 hasAuthorship W2114068656A5053223845 @default.
• W2114068656 hasAuthorship W2114068656A5076666408 @default.
• W2114068656 hasAuthorship W2114068656A5087720227 @default.
• W2114068656 hasBestOaLocation W21140686561 @default.
• W2114068656 hasConcept C170493617 @default.
• W2114068656 hasConcept C202751555 @default.
• W2114068656 hasConcept C203014093 @default.
• W2114068656 hasConcept C2775960820 @default.
• W2114068656 hasConcept C2776362946 @default.
• W2114068656 hasConcept C2779438470 @default.
• W2114068656 hasConcept C2780269544 @default.
• W2114068656 hasConcept C2780381497 @default.
• W2114068656 hasConcept C502942594 @default.
• W2114068656 hasConcept C55493867 @default.
• W2114068656 hasConcept C57074206 @default.
• W2114068656 hasConcept C58207958 @default.
• W2114068656 hasConcept C62478195 @default.
• W2114068656 hasConcept C86803240 @default.
• W2114068656 hasConcept C95444343 @default.
• W2114068656 hasConceptScore W2114068656C170493617 @default.
• W2114068656 hasConceptScore W2114068656C202751555 @default.
• W2114068656 hasConceptScore W2114068656C203014093 @default.
• W2114068656 hasConceptScore W2114068656C2775960820 @default.
• W2114068656 hasConceptScore W2114068656C2776362946 @default.
• W2114068656 hasConceptScore W2114068656C2779438470 @default.

• next